Nephropathy, interstitial pneumopathy, and renal and lung fibrosis are major complications of bone marrow transplantation (BMT). This study evaluated the antifibrotic property of an angiotensin II (A2) type-1 receptor blocker (L-159,809) and compared it with those of Captopril and Enalapril, two angiotensin-converting enzyme (ACE) inhibitors, in a rat model of BMT. Male WAG/Rij/MCW rats received a preparative regimen of 60 mg/kg body wt of cytoxan (i.p., Days 9 and 8) and 18.5 Gy of total body irradiation (TBI) in six twice daily fractions (Days 2, 1, and 0) followed immediately (Day 0) by BMT. Modifiers were given in drinking water from Day 10 until autopsy, 8 weeks after BMT. Rats treated with TBI plus cytoxan alone developed severe nephropathy. Trichrome staining showed marked collagen deposition in glomeruli, renal interstitium, and renal arteries and arterioles (especially in their adventitia). Collagen deposition and renal damage were markedly reduced by the three modifiers. Of the three, L-158,809-treated rats had slightly thinner vessels and slightly less collagen than nonirradiated normal controls. The study shows the effectiveness of these drugs in the protection of the renal parenchyma from the development of radiation-induced fibrosis. It also indicates a role for angiotensin II in the modulation of collagen synthesis.
AsscherAW. Prevention of renal damage by x-rays. Br J Radiol38:533–535, 1965.
2.
WardWF, MolteniA, Ts'aoCH, SollidayNH. Functional responses of the pulmonary endothelium to thoracic irradiation in rats: differential modification by D-penicillamine. Int J Radiat Oncol Biol Phys13:1505–1509, 1987.
3.
DionMW, HusseyDH, OsborneJW. The effect of pentoxifilline on early and late radiation injury following fractionated irradiation in C34 mice. Int J Radiat Oncol Biol Phys17:101–107, 1989.
4.
GeraciJP, MarianoMS, JacksonKL. Amelioration of radiation nephropathy in rats by dexamethasone treatment after irradiation. Radiat Res134:86–93, 1993.
5.
CohenEP, FishBL, MoulderJE. Treatment of radiation nephropathy with Captopril. Radiat Res132:346–350, 1992.
6.
CohenEP, MolteniA, HillP, FishBL, WardWF, MoulderJE, CaroneFA. Captopril preserves function and ultrastructure in experimental radiation nephropathy. Lab Invest75:349–360, 1996.
7.
WardWF, MolteniA, Ts'aoCH, KimYT, HinzJM. Radiation pneumotoxicity in rats: modification by inhibitors of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys22:623–625, 1992.
8.
YaromR, HarperIS, WynchankS, van SchalkwykD, MadhooJ, WilliamsK, SalieR, GenadeS, LochnerA.Effects of Captopril on changes in rats' hearts induced by long-term irradiation. Radiat Res133:187–197, 1993.
9.
PowellJS, ClozelJP, MullerRK, KuhnH, HeftiF, HosangM, BaumgartnerHR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science245:186–188, 1989.
10.
NguyenL, WardWF, Ts'aoCH, MolteniA.Captopril inhibits proliferation of human lung fibroblasts in culture: a potential antifibrotic mechanism. Proc Soc Exp Biol Med205:80–84, 1994.
11.
ReddyMK, BaskaranK, MolteniA.Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med210:221–227, 1995.
12.
SmallWJr, WardWF, MolteniA, KimYT, TaylorJM. Captopril-modulated hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture. Breast Cancer Res Treat44:217–224, 1997.
13.
VolpertOV, WardWF, LingenM, CheslerL, SoltD, JohnsonM, MolteniA, PolveriniPJ, BouckNP. Captopril is an inhibitor of angiogenesis that is able to slow the growth of experimental tumors in rats. J Clin Invest98:671–679, 1996.
14.
RobertsMA, RobinsonPA. Copper chelates of antirheumatic and anti-inflammatory agents and their superoxide dismutase-like activity and stability. Br J Rheumatol24:128–136, 1985.
15.
WestlinW, MullaneK.Does Captopril alter reperfusion-induced myocardial dysfunction by scavenging free radicals?Circulation77(Suppl I):130–134, 1988.
16.
ChristieGL, HughesMA, ReesSB, WilliamsDR. The binding of metal ions by Captopril (SQ4225): Part II. Completion of copper. Inorgan Chim Acta151:215–227, 1988.
17.
SieglPKS, ChangRSL, MantioNB, ChakravartyPK, OndeykaDL, GreenleeWJ, PatchettAA, SweetCS, LottiVJ. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. J Pharm Exp Ther262:139–144, 1992.
18.
MoulderJE, FishBL, AbramsRA. Renal toxicity following total body irradiation and syngeneic bone marrow transplantation. Transplantation43:589–592, 1987.
19.
CohenEP, MoulderJE, FishBL, HillP.Prophylaxis of experimental bone marrow transplant nephropathy. J Lab Clin Med124:371–380, 1994.
20.
MoulderJE, FishBL. Late toxicity of total body irradiation with bone marrow transplantation in a rat model. Int J Radiat Oncol Biol Phys16:1501–1509, 1989.
MoulderJE, FishBL, CohenEP. Treatment of radiation nephropathy with ACE inhibitors. Int J Radiat Oncol Biol Phys27:93–99, 1993.
24.
MolteniA, WardWF, Ts'aoCH, SollidayNH, DunneM.Monocrotaline-induced pulmonary fibrosis in rats: amelioration by Captopril and penicillamine. Proc Soc Exp Biol Med180:112–117, 1985.
25.
KeeleyFW, ElmoselhiA, LeenenFHH. Enalapril suppresses normal accumulation of elastin and collagen in cardiovascular tissues of growing rats. Am J Physiol262:H1013–H1021, 1992.
26.
KanetoH, MorriseyJ, McCrackenR, ReyesA, KlahrS.Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. Kidney Int45:1637–1647, 1994.
27.
MoulderJE, FishBL, CohenEP, BonsibSM. Angiotensin II receptor antagonists in the prevention of radiation nephropathy. Radiat Res146:106–110, 1996.
28.
MolteniA, MoulderJE, CohenEF, WardWF, FishBL, TaylorJM, WolfeLF, Brizio-MolteniL, VenoP.Control of radiation induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Rad Biology76(4):523–532, 2000.
29.
MarshallR, GoldsackN, MutsaersS, McAnultyR, LaurentG.Angiotensin 2: a novel mediator of pulmonary fibrosis? Proceedings 10th International Colloquium on Lung Fibrosis. Siena, Italy, October 11–14, 1998.
30.
WeaverJ, MolteniA, AlbertsonD, SollidayN, CelicL.Effect of angiotensin I-converting enzyme inhibitor tepromide (SQ20881) on serum aldosterone in the rat. Lab Invest45:527–533, 1981.
31.
HuangCM, Del GrecoF, QuintanillaA, MolteniA.Angiotensin-converting enzyme inhibition by Captopril in essential hypertension. J Am Med Assoc245:478–482, 1981.
32.
MolteniA, ZakheimRM, MullisKB, MattioliL.Effect of chronic hypoxia on renin and angiotensin 1-converting enzyme in the mouse. Proc Soc Exp Biol Med147:283, 1974.
33.
ZakheimRM, MattioliL, MolteniA, MullisKB, BartleyJ.Prevention of pulmonary vascular changes of chronic alveolar hypoxia by inhibition of angiotensin-converting enzyme in the rat. Lab Invest35:57–62, 1975.
34.
ZakheimRM, MolteniA, MattioliL, MullisKB. Angiotensin-II levels during acute and chronic hypoxia in the unanesthetized rabbit. J Appl Physiol41:462, 1976.
35.
ZakheimRM, BodolaF, ParkMK, MolteniA, MattioliL.Renin angiotensin system in the Llama. J Comp Physiol Biochem59:375–379, 1979.
36.
MolteniA, SollidayNH, Ts'aoCH, WardW.Monocrotaline-induced pulmonary changes in rats: amelioration by the angiotensin I-converting enzyme inhibitor CL 242817. Proc Soc Exp Biol Med182:483–489, 1986.
37.
MolteniA, WardWF, Ts'aoCH, SollidayNH. Monocrotaline-induced cardio-pulmonary injury in rats: modification by thiol and non-thiol ACE inhibitors. Hypertension. Clin ExpA9(2 and 3):381–386, 1987.
MolteniA, WardWF, Ts'aoCH, SollidayNH. Monocrotaline-induced cardio-pulmonary injury in rats: modification by the non-thiol ACE inhibitors CGS 13945 and CGS 16617. Arch Int Pharmacodyn Ther292:21–29, 1988.
40.
TallantAE, DizDI, FerrarisCM. Antiproliferative actions of angiotensin (1–7) in vascular smooth muscle. Hypertension34(2):950–957, 1999.
